Royal Bank of Canada
TTRX

Royal Bank of Canada’s Turn Therapeutics TTRX Stock Holding History

Royal Bank of Canada’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-267
Closed -$1K – 7938
2025
Q4 		$1K Buy
+267
New +$1.11K ﹤0.01% 7105

Other funds holding TTRX

DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's TTRX Position: Q1 2026 in Review

Royal Bank of Canada sold out of Turn Therapeutics (TTRX) in Q1 2026, closing a stake of 267 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in TTRX in Q4 2025 and held it in 1 quarter. The position peaked at $1K in Q4 2025. 20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

  • Royal Bank of Canada reported no remaining Turn Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 267 Turn Therapeutics shares in Q1 2026, an estimated $1K.
  • Royal Bank of Canada first reported a position in Turn Therapeutics in Q4 2025 and held it in 1 quarter.
  • Royal Bank of Canada's Turn Therapeutics position peaked at $1K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.